Eksenatid

Eksenatid
Klinički podaci

Prodajno ime	Byetta, Byetta (Amylin/Eli Lilly)
Drugs.com	Monografija
Način primene	Subkutano
Farmakokinetički podaci
Poluvreme eliminacije	2,4 h
Izlučivanje	Renalno

Identifikatori
CAS broj	141758-74-9^Y
ATC kod	A10BX04 (WHO)
DrugBank	DB01276^Y
Hemijski podaci
Formula	C₁₈₄H₂₈₂N₅₀O₆₀S
Molarna masa	4186.6

Eksenatid (INN, Byetta, Bydureon) agonist je glukagonu sličnog peptida-1 (GLP-1 agonist). On pripada grupi mimetika inkretina. Ovaj lek je odobren aprila 2005. za lečenje dijabetes melitusa tipa 2.^[1]^[2]^[3]

Reference

^ Heine RJ, Van Gaal LF, Johns D, Mihm MJ, Widel MH, Brodows RG: Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med. 2005 Oct 18;143(8):559-69. PMID 16230722
^ Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, Djoumbou Y, Eisner R, Guo AC, Wishart DS (2011). „DrugBank 3.0: a comprehensive resource for omics research on drugs”. Nucleic Acids Res. 39 (Database issue): D1035—41. PMC 3013709 . PMID 21059682. doi:10.1093/nar/gkq1126. уреди
^ David S. Wishart; Craig Knox; An Chi Guo; Dean Cheng; Savita Shrivastava; Dan Tzur; Bijaya Gautam; Murtaza Hassanali (2008). „DrugBank: a knowledgebase for drugs, drug actions and drug targets”. Nucleic acids research. 36 (Database issue): D901—6. PMC 2238889 . PMID 18048412. doi:10.1093/nar/gkm958. уреди

Hardman JG, Limbird LE, Gilman AG (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10. изд.). New York: McGraw-Hill. ISBN 0071354697. doi:10.1036/0071422803.
Thomas L. Lemke; David A. Williams, ур. (2007). Foye's Principles of Medicinal Chemistry (6. изд.). Baltimore: Lippincott Willams & Wilkins. ISBN 0781768799.